Aliada Therapeutics Overview
- Year Founded
-
2021
- Status
-
Acquired/Merged
- Employees
-
20
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1.4B
Aliada Therapeutics General Information
Description
Developer of drug development therapy designed to treat central nervous system diseases. The company applies its novel technology to specific central nervous system target antibody binders and progress programs through preclinical evaluation, enabling medical professionals to treat central nervous system diseases.
Contact Information
Website
www.aliadatx.comCorporate Office
- 501 Boylston Street
- 9th Floor
- Boston, MA 02116
- United States
Corporate Office
- 501 Boylston Street
- 9th Floor
- Boston, MA 02116
- United States
Aliada Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 11-Dec-2024 | $1.4B | Completed | Generating Revenue | ||
| 3. Early Stage VC | 30-Dec-2022 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 06-Jul-2021 | $1M | $21M | Completed | Startup | |
| 1. Seed Round | $20M | $20M | Completed | Startup |
Aliada Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed-1 | ||||||||
| Seed |
Aliada Therapeutics Patents
Aliada Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021253821-A1 | Anti-cd98 antibodies and uses thereof | Pending | 08-Apr-2020 | ||
| CA-3179922-A1 | Anti-cd98 antibodies and uses thereof | Pending | 08-Apr-2020 | ||
| EP-4132974-A1 | Anti-cd98 antibodies and uses thereof | Pending | 08-Apr-2020 | ||
| EP-4132974-A4 | Anti-cd98 antibodies and uses thereof | Pending | 08-Apr-2020 | ||
| US-20230174669-A1 | Anti-cd98 antibodies and uses thereof | Pending | 08-Apr-2020 | C07K16/2896 |
Aliada Therapeutics Signals
Aliada Therapeutics Former Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Johnson & Johnson JJDC | Corporate Venture Capital | Minority | ||
| OrbiMed | Growth/Expansion | Minority | ||
| RA Capital Management | Asset Manager | Minority | ||
| Sanofi Ventures | Corporate Venture Capital | Minority |
Aliada Therapeutics FAQs
-
When was Aliada Therapeutics founded?
Aliada Therapeutics was founded in 2021.
-
Where is Aliada Therapeutics headquartered?
Aliada Therapeutics is headquartered in Boston, MA.
-
What is the size of Aliada Therapeutics?
Aliada Therapeutics has 20 total employees.
-
What industry is Aliada Therapeutics in?
Aliada Therapeutics’s primary industry is Discovery Tools (Healthcare).
-
Is Aliada Therapeutics a private or public company?
Aliada Therapeutics is a Private company.
-
What is the current valuation of Aliada Therapeutics?
The current valuation of Aliada Therapeutics is .
-
What is Aliada Therapeutics’s current revenue?
The current revenue for Aliada Therapeutics is .
-
How much funding has Aliada Therapeutics raised over time?
Aliada Therapeutics has raised $53M.
-
Who are Aliada Therapeutics’s investors?
Johnson & Johnson JJDC, OrbiMed, RA Capital Management, and Sanofi Ventures have invested in Aliada Therapeutics.
-
When was Aliada Therapeutics acquired?
Aliada Therapeutics was acquired on 11-Dec-2024.
-
Who acquired Aliada Therapeutics?
Aliada Therapeutics was acquired by AbbVie.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process